With March Madness in full swing, we decided to stick with what we know here at The Motley Fool, trading our basketball picks in for stock picks. We formed our own bracket filled with the top Big Pharma and Big Biotech stocks in a winner take-all tournament determined by the collective intelligence of our CAPS community.
This championship round matchup features Celgene and Abbott Labs. Like the injury suffered to Louisville's Kevin Ware, Abbott is missing a key piece after the spin-off of AbbVie. Celgene is playing the role of Michigan, with a roster of known stars (Revlimid as Trey Burke), along with emerging talents (Abraxane as Mitch McGary).
Watch and find out which company cuts down the nets as health care's best stock.
Abbott Labs has changed forever after losing its branded pharmaceutical business to a spinoff. If you're a current investor, or might be buying shares soon, make sure you truly understand the stock by reading The Motley Fool's brand new premium report on Abbott Labs. The report outlines all of the must-know opportunities and risks, along with a full year of analyst updates to keep you up to speed. Best of all, you can claim this report today by clicking here now.
The article Health Care's Best Stock: Celgene vs. Abbott Labs originally appeared on Fool.com.
Max Macaluso, Ph.D., and David Williamson have no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.